t hard-to-drug targets. Nimbus Discovery harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. Nimbus focuses on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Nimbus' rob

the for-profit side, Boris led investments in various life science/health care companies such as Foundation Medicine, Research Gate, Schrodinger and Nimbus through Bill Gates Ventures. On the non-for profit side, Boris co-managed BMGF's $1.5 billion strategic investment pool focused on program-related

...1mi~ DOMMAC• !Wm.". err... ,11.4p 6749 LIPUTYUI Saguia. { 0..(w.% wMnrnr raid Iris, Mu" Pia ~WI VS S "renal REAL WAYS ~scar J tor 1 Nimbus ~Nee by ma% PsetBentCollIthemidetc. tat «St tot "a. clou S aO,nmont mute rem& l'aliPSEPPCJINI Mein COIn i PnVap POICS I Al^l Wr Si* http://www.pal

ined by Nimbus Discovery, LLC ("Nimbus") in mid-January 2014. Ms. Tran informed the Board that (i) the bridge investors' equity would sit on top of Nimbus' existing investors' equity such that the bridge investors would be paid out in the event of a distribution of proceeds by Nimbus and that (ii) the

life- science/IT/healthcare companies such as Foundation Medicine and Research Gate, served on the board of directors of Schrodinger, and monitored Nimbus. On the not-for-profit side, Dr. Nikolic co- managed BMGF's $1.5 billion strategic-investment pool, focused on program-related investments in health